Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.86 and traded as low as $0.82. Seres Therapeutics shares last traded at $0.84, with a volume of 1,756,033 shares trading hands.
Wall Street Analyst Weigh In
MCRB has been the topic of a number of recent research reports. Chardan Capital reiterated a "buy" rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. StockNews.com downgraded Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, January 11th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Seres Therapeutics currently has a consensus rating of "Hold" and an average price target of $5.08.
Get Our Latest Stock Report on MCRB
Seres Therapeutics Price Performance
The firm's fifty day moving average price is $0.86 and its two-hundred day moving average price is $0.90. The stock has a market cap of $144.26 million, a P/E ratio of -3.67 and a beta of 2.13.
Hedge Funds Weigh In On Seres Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC raised its stake in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after buying an additional 18,191 shares during the period. Point72 DIFC Ltd bought a new position in shares of Seres Therapeutics in the second quarter worth about $64,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Seres Therapeutics in the second quarter worth about $92,000. Providence Wealth Advisors LLC raised its stake in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after buying an additional 22,250 shares during the period. Finally, State Street Corp raised its stake in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after buying an additional 43,700 shares during the period. Institutional investors own 59.34% of the company's stock.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Read More
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
